ストックスクリーナーアプリを入手
240.34
0.48%
1.15
プレマーケット:
239.90
-0.44
-0.18%
前日終値:
$239.19
開ける：
$240.24
24時間の取引高:
1.01M
Relative Volume:
0.76
時価総額：
$33.52B
収益：
$2.12B
当期純損益:
$-309.19M
株価収益率:
-105.22
EPS:
-2.2841
ネットキャッシュフロー:
$93.57M
1週間 パフォーマンス:
+0.33%
1か月 パフォーマンス:
+5.23%
6か月 パフォーマンス:
+60.39%
1年 パフォーマンス:
+41.09%
1日の値動き範囲:
$234.51
$243.03
1週間の範囲:
$226.12
$243.47
52週間の値動き範囲:
$125.38
$256.36
Natera Inc Stock (NTRA) Company Profile
NTRA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NTRA
Natera Inc
|
240.34 | 33.35B | 2.12B | -309.19M | 93.57M | -2.2841 |
|
TMO
Thermo Fisher Scientific Inc
|
624.65 | 233.63B | 43.74B | 6.58B | 6.11B | 17.31 |
|
DHR
Danaher Corp
|
239.89 | 168.08B | 24.27B | 3.50B | 5.02B | 4.8589 |
|
IDXX
Idexx Laboratories Inc
|
712.12 | 56.73B | 4.17B | 1.03B | 940.22M | 12.61 |
|
IQV
Iqvia Holdings Inc
|
241.28 | 41.10B | 15.90B | 1.28B | 2.21B | 7.2842 |
|
A
Agilent Technologies Inc
|
144.83 | 41.37B | 6.95B | 1.30B | 1.15B | 4.5696 |
Natera Inc Stock (NTRA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-07 | 開始されました | Citigroup | Buy |
| 2025-12-02 | 再開されました | Morgan Stanley | Overweight |
| 2025-10-27 | アップグレード | BNP Paribas Exane | Underperform → Neutral |
| 2025-09-22 | 再開されました | Wells Fargo | Equal Weight |
| 2025-03-13 | 開始されました | RBC Capital Mkts | Outperform |
| 2025-01-23 | 開始されました | Barclays | Overweight |
| 2024-06-03 | 再開されました | Jefferies | Buy |
| 2024-04-08 | 再開されました | Craig Hallum | Buy |
| 2024-02-20 | ダウングレード | Raymond James | Strong Buy → Outperform |
| 2023-12-29 | 繰り返されました | BTIG Research | Buy |
| 2023-12-14 | 開始されました | Guggenheim | Buy |
| 2023-12-13 | 開始されました | Wolfe Research | Outperform |
| 2023-11-13 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2023-09-28 | 開始されました | Bernstein | Mkt Perform |
| 2023-07-05 | 再開されました | JP Morgan | Overweight |
| 2023-05-05 | 開始されました | UBS | Buy |
| 2023-01-18 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2022-08-25 | 開始されました | Credit Suisse | Outperform |
| 2022-04-25 | 開始されました | Stephens | Overweight |
| 2022-03-08 | 開始されました | Goldman | Buy |
| 2022-01-06 | 再開されました | Piper Sandler | Overweight |
| 2021-10-15 | 再開されました | Cowen | Outperform |
| 2021-06-15 | 開始されました | Raymond James | Mkt Perform |
| 2021-05-25 | 開始されました | Wells Fargo | Overweight |
| 2021-01-28 | 開始されました | Truist | Buy |
| 2020-10-08 | 開始されました | BTIG Research | Buy |
| 2020-09-28 | 開始されました | Morgan Stanley | Overweight |
| 2020-09-17 | 開始されました | SVB Leerink | Outperform |
| 2020-06-10 | 再開されました | Piper Sandler | Overweight |
| 2020-05-07 | アップグレード | JP Morgan | Neutral → Overweight |
| 2018-10-05 | 開始されました | JP Morgan | Neutral |
| 2018-07-05 | 繰り返されました | Piper Jaffray | Overweight |
| 2017-08-07 | 繰り返されました | Morgan Stanley | Overweight |
| 2016-11-10 | 繰り返されました | The Benchmark Company | Buy |
| 2016-05-23 | 繰り返されました | The Benchmark Company | Buy |
| 2016-05-11 | 繰り返されました | The Benchmark Company | Buy |
| 2016-04-19 | 開始されました | The Benchmark Company | Buy |
| 2015-09-28 | アップグレード | Wedbush | Neutral → Outperform |
| 2015-08-14 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2015-08-04 | 開始されました | Robert W. Baird | Outperform |
| 2015-07-27 | 開始されました | Morgan Stanley | Equal-Weight |
| 2015-07-27 | 開始されました | Piper Jaffray | Overweight |
| 2015-07-27 | 開始されました | Wedbush | Neutral |
すべてを表示
Natera Inc (NTRA) 最新ニュース
Is It Too Late To Consider Natera (NTRA) After Its Strong 1-Year Share Price Run? - simplywall.st
Natera Targets Endometrial Cancer With New Signatera Trial, Expanding Its MRD Opportunity - TipRanks
Sumitomo Mitsui Trust Group Inc. Sells 88,968 Shares of Natera, Inc. $NTRA - MarketBeat
Assessing Whether Natera (NTRA) Is Overvalued After Strong Longer Term Share Price Gains - Yahoo Finance
Natera unveils AI model to enhance cancer recurrence risk assessment By Investing.com - Investing.com Nigeria
How Investors Are Reacting To Natera (NTRA) NVIDIA-Backed Multimodal AI And Precision Diagnostics Advances - Yahoo Finance
Natera’s SCORE Study Builds Real-World Evidence for Cancer MRD Testing - TipRanks
NTRA & NVDA Partner to Improve AI Models for Precision Medicine - Nasdaq
Natera, Inc. Announces Next Breakthrough in MRD-Based Risk Stratification, Leveraging Multi-Modal AI Modeling - marketscreener.com
Natera unveils AI model to enhance cancer recurrence risk assessment - Investing.com
Natera Announces Next Breakthrough in MRD-Based Risk Stratification, Leveraging Multi-Modal AI Modeling - Yahoo Finance
Natera: Accelerating MRD Momentum, Revenue Outperformance, and Improving Cash Profile Support Buy Rating - TipRanks
(NTRA) and the Role of Price-Sensitive Allocations - Stock Traders Daily
JP Morgan lifts Natera, Inc. (NTRA) target on Signatera momentum - MSN
Natera’s updated prenatal test, Fetal Focus, adds Gaucher disease - Gaucher Disease News
Natera (NTRA) Joins Forces with NVIDIA to Boost AI in Precision Medicine - GuruFocus
Nvidia enters collaboration with Natera - TipRanks
Natera to Scale AI Foundation Models in Precision Medicine with NVIDIA - marketscreener.com
Natera stock rises as Canaccord maintains Buy rating on strong preliminary results - Investing.com Nigeria
Natera stock rises as Canaccord maintains Buy rating on strong preliminary results By Investing.com - Investing.com South Africa
Natera (NTRA) Reports Robust Q4 and FY 2025 Revenue Growth - GuruFocus
Natera Q4 Preliminary Revenue Rises; Shares Up Pre-Bell - marketscreener.com
Natera Announces Strong Preliminary Fourth Quarter and 2025 Financial Results Driven by Record Signatera™ Growth - BioSpace
NTRA Reports Strong FY25 Revenue and Test Volume Growth - GuruFocus
Natera Q4 prelim revenue beats on oncology tests boost - TradingView — Track All Markets
Breakeven On The Horizon For Natera, Inc. (NASDAQ:NTRA) - Yahoo Finance
Natera, Inc.'s (NASDAQ:NTRA) Business Is Yet to Catch Up With Its Share Price - 富途牛牛
Natera (NASDAQ:NTRA) Stock Rating Upgraded by Citigroup - MarketBeat
Market Catalysts: Is Natera Inc. stock attractive after correctionWatch List & Consistent Income Trade Ideas - Улправда
Natera (NTRA) announces publication of findings from randomized, phase III CALGB (Alliance)/SWOG 80702 study - MSN
Non-Invasive Prenatal Testing Market is expected to generate a revenue of USD 9.83 Billion by 2031, Globally, at 17.01% CAGR: Verified Market Research® - GlobeNewswire Inc.
Natera, Inc. $NTRA Shares Acquired by SG Americas Securities LLC - MarketBeat
How Natera ctDNA Partnership Around STELLAR-316 At Exelixis (EXEL) Has Changed Its Investment Story - Yahoo Finance
Will Natera Inc. stock outperform tech sector in 2025Insider Buying & Real-Time Stock Entry Alerts - ulpravda.ru
Can Natera Inc. stock sustain market leadership2025 AllTime Highs & Risk Controlled Stock Pick Alerts - ulpravda.ru
Is Natera Inc. stock attractive for growth ETFs2025 Top Gainers & Free High Accuracy Swing Entry Alerts - ulpravda.ru
NTRANatera Inc Latest Stock News & Market Updates - Stock Titan
Natera (NASDAQ:NTRA) Shares Down 7.6%What's Next? - MarketBeat
Will Natera Inc. stock gain from strong economyQuarterly Portfolio Report & Risk Adjusted Buy/Sell Alerts - Улправда
Can Natera Inc. stock weather global recessionJuly 2025 Momentum & Reliable Entry Point Alerts - ulpravda.ru
Can Natera Inc. stock beat analyst upgradesJuly 2025 Opening Moves & Real-Time Chart Pattern Alerts - ulpravda.ru
EXEL Collaborates With Natera for Late-Stage Colorectal Cancer Study - Finviz
Exelixis and Natera to collaborate on MRD-guided cancer trial By Investing.com - Investing.com Nigeria
Citigroup Initiates Buy Rating on Natera (NTRA) with $300 Price Target | NTRA Stock News - GuruFocus
Assessing Natera (NTRA) Valuation After Positive ALTAIR Trial Data And Expanded Fetal Focus Test Launch - simplywall.st
Medical stock hovers near buy point after 46% gain - MSN
Why Natera’s Stock Is Sliding Despite Bullish Outlook - TipRanks
Trade Tracker: Stephanie Link sells Eaton and buys more Zoetis, Natera - CNBC
Exelixis and Natera stocks rise on colorectal cancer trial collaboration By Investing.com - Investing.com Australia
Exelixis and Natera stocks rise on colorectal cancer trial collaboration - Investing.com
Exelixis, Natera to Collaborate on Phase 3 Colorectal Cancer Trial - marketscreener.com
Natera Inc (NTRA) 財務データ
収益
当期純利益
現金流量
EPS
0.74%
0.75%
大文字化:
|
ボリューム (24 時間):